PGEN - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to Precigen Fourth Quarter and Yearend 2020 Financial Results Conference call. [Operator Instructions]. I'd now like to turn the conference over to Steven Harasym. Please go ahead.

Steven Harasym

Thank you, operator and thank you all for joining us today. Dr. are me With and Strategy. Precigen; President Head Tom of Financial CEO Sabzevari, and of Samuelson, Helen provide update quarter will Tom Helen an will after and review which technologies, our fourth XXXX results. on financial our pipeline

prepared the Q&A. remarks, call the Following to open we'll

review let's forward-looking statements. Before briefly we our begin,

to differ that expectations that During call, presentation to and statements. by safe well or in to and Dr. uncertainties cautioned to Please are statement cause filings discussion indicated I'll read the make turn harbor recent Sabzevari? statements actual are like risks most outcomes the statements. Investors various contained subject from today's forward-looking for contained the forward-looking based in could factors call our these this results more will complete uncertainties. are we those of as over our risk a SEC materially on as current and risks Precigen's forward-looking now

Helen Sabzevari

execute a delivering transformative to am year for thank patient today. connect families was our time and healthy. and you of and continues highlights our the in their mission of achieve is our ways. to of safe taking this proud Thanks very to today you of financial Precigen unmet medical results. all XXXX. stakeholders viewing novel truly It XXXX all to to options I to treatment great work with need. team hope Steve finds It I several and our everyone in achievement us with and listen review to call

trial and and continuity. safety foremost, measures health to clinical First and research we implemented ensure

challenging milestones all meet during able As a a we were of our result, stated clinical year. very to

major portfolio year, optimizing a Throughout innovative the strides operation exciting therapeutic become our and focused, transitioned health-focused successfully to of to we company nimble the more in candidate. Second, advancing our company. made

our in a on details discipline. we numbers the will our later quarterly through and a raise fiscal position capital provide call. Third, fortified financial Tom additional

across position portfolio and an our manufacturing advances made we completing milestones clinical that for off XXXX. us meaningful Finally, important exciting

of portfolio recap moving our progress. a Now to

transformative our UltraCAR-T First, platform.

XXXX, this on solid have robust vivo goal expansion shown multiple demonstrated in Furthermore, even presented and for started lymphoid we ability data and dose for of we was setting. update Based either to lowest during cells dose cell. will demonstrate our the tumor activity and neurotoxicities validate in an our encouraging UltraCAR-T profile year need in our demonstrate decentralized As be December, date we to across sites excellent our the manufacturing CAR-T in safety the or with vivo without and overnight trial. main manufacture in persistent and persistent platform expansion successfully depletion cohort, in in demonstrated our no the hematological both clinical to call limiting

commercially the platform cost software hematological cells the reducing time clinical dosing This manufacturing for have a patients therapeutic CAR-T system intended introduction for advancing was represents at a solution aimed auction. scalable solution system of for FDA started cleared we UltraCAR-T both by significantly using solid electroporation used devices contamination current advancement UltraPorator and over and by trial. our tumor with major risk. a manufacturing UltraCAR-T we and commercialization to addition, high includes and throughput UltraPorator, UltraPorator of The potentially In viable viable is becoming up manufacturing. towards and scale our hardware and decentralized and be semi-closed,

low-dose persistent patients at Initial trail showed targeting lymphodepletion. X Phase ovarian As UltraCAR-T for December in without with and presented data infusion after XB trial, for encouraging PRGN-XXXX unshed MUCXX the IP PRGN-XXXX cells cancer. in

recent and level and doses total regression In one lymphodepletion tumor UltraCAR-T either addition between target experienced two, low treated in of level XX% million had six no cells dose three out dose million burden patients of XX six, with or with to these phase in restaging at in of expansion forward of out the the according the initiating IP the criteria stable disease half looking we evaluation. achieved to are two six are expansion second patients continues Dose XXXX. a

We PRGN-XXXX leukemia from Annual have and myeloid to of for we dosed arm the and concurrently acute with the study have ASH syndrome first higher and Phase data announce refractory X ongoing IPR I'm announced trial received Phase happy risk to FDA IV that Meeting with in clinical December. or encouraging X/XB IVR dysplastic the successfully PRGN-XXXX now initiate clearance dosing station the and patients at relapsed myeloid from in we in the AML

ASH As while Dr. presented at PI, our

million cells persist UltraCAR-T blood achieved to X in in patient stem for patient received million blood cohort PRGN-XXXX Solomon now PRGN-XXXX X prior low am hematopoietic marrow the had as bone with very clinical concomitant level after and The update both well total levels showed I cells lymphodepletion. with response UltraCAR-T PRGN-XXXX objective by well blood doing lymphodepletion months and stable disease. bone XXXX it, At who UltraCAR-T showed where million our cells an in tumor report according and as December, seven patient infusion lymphodepletion which encouraging ELN subsequently persistence to highlighted infusion an cell cases had million AML a and in XX and without indicated pleased activity transplant and dose track and the as criteria. Furthermore study per non-lymphodepletion peripheral platform marrow. received ability and a low-dose in had in is expansion This that treatment of evidenced in of blast between only with CRI Dr. expand XX reduction cells one a after more with a to strength and had expansion persistent dose level. approximately this than persisted at potential was ASH the prior failures multiple treatment UltraCAR-T this patient and decline

second dose half these the to ongoing providing encouraging of upcoming in updates on We're non-lymphodepletion at the track outcome. XXXX. of forward the medical expansion investigators very clinical and phase We arms enrolling is conferences. and the trial look simultaneously Solomon on initiate lympho both in escalation phase are our to

As a precision validation tool creating of the the provide a way we continue to to believe platform, we for we on clinical UltraCAR-T are medicine.

goal is a of patient's and you response rebuilding of be validate indication antigen to non-viral same to has the autologous would profile, re-dosing from After approach UltraCAR-T tumor-associated expression very at target allow if has library to advancement needed that the of to prospect so UltraCAR-T treatment. do or plasmid patients, personalized the based non-viral generate in antigen. biomarker antigen to tumor-associated medicine. plasma on We the only cancel this flexibility the to is or and a exciting more the initial UltraCAR-Thank selected targeting Our the for library at Based time one this the multiple has believe the a lowest potential develop on platform treatment, personalized cost. the for This build new is and treatment tumor. for the patient same changes the of potential of the

on adenovector a competing bold Now payload let's it start to provides high capacity in ability has is the to and the our worst to advantages which gorilla those immunotherapy approaches. library, based platform read

the post in differentiation level January was trial of X, solid dose of moving under in demonstrated one, class resulted CRADA an toxicity. Preliminary breadth positive in we NCI. to existing months. in three encouraged patient patients which with adenovirus In platform the administration. PRGN-XXXX treat dosed update the increase X with first treatment. to our is administration PRGN-XXXX, treated specific a the Now tumors August, XXX% HPV and in announced HPV and a further preliminary have we forward PRGN-XXXX at Phase a response. HPVXX cell in Phase in magnitude escalation to This of of out to We and arm the repeat were multiple the dose limiting responses and co-relative compared of three six increase in well-tolerated that highlights coming patients completion the HPVXX Furthermore, and/or analysis monotherapy with enrolled T of finding to-date showed arm immune I announced an providing monotherapy look the in administration trial. I PRGN-XXXX of repeated potential received the specific phase very enrollment dose a has All doses no been first Phase

have the in X MXXXX. interim PRGN-XXXX initiate We of dosing XXXX to portion and a includes in an and which timeframe. in of anticipate the X Phase portion same the tribe initiated half of Phase trial, the second the readout combo We

moving PRGN-XXXX that to dosing RRP. half or disease. Now infectious XXXX. treatment we the on Phase an is targeting the trial had initiate and of to the program first papillomatosis announced initial PRGN-XXXX, application our off-the-shelf cleared is first adenovirus XXXX, X investigational for recurrent we the FDA respiratory expect immunotherapy which In clinical of January

in a key decreased that chronic and data HBV by level incorporate design candidate showed HBV novel vaccine plasma marker this B encouraged PRGN-XXXX T data in January a or AdenoVerse cell in antigen in therapy gorilla adenovector. PRGN-XXXX advance program We're for opportunity a against mice be toward The this HBV very epitopes competitor This data more to preclinical superior clinic for the infectious infection. induced infection. for antigen responses HBV disease. therapy cytotoxic presented that and hepatitis surface B hepatitis Finally,

platform. to moving is Now active which AGXXX, Phase a based Xb/Xa on our trial biotics of

following TXD of have to treatment insulin an data trend December, In level ability from of in only for treatment the AGXXX trial. combination. cycle IIA Phase showing and Xb/Xa the provided or completed trial antigen-specific of of one a in we modulation AGXXX immune portion in the enrollment monotherapy the Phase positive induce We encouraging arm oral as C-peptide

and in Xa provide with of during regulatory Phase goal the XX-month of advance We're XXXX engaged the for the the with in adult XXXX. Phase agencies into rapidly first phase during program the the We design to this the BLA. in trial next data adolescence arm second half expect half Xa toward the the follow-up the portion to arm

our XX with speak, partnering solid in activity study safety discussion. we X clinical INXN-XXXX for and we trial and as this have are I actively for in Finally, the involved completed heart month encouraging we failure, Phase profile Phase follow-up

Tom? I to Tom financial turn Now an will our call of results. overview for the over

Tom Samuelson

afternoon stakeholders on the Thank you, and Helen to our call. good

contributors financial nonhealth be be operating year, capital to we highly to $XXX.X product were the transitioning pursuing defined capital, reductions to to total to expenses plus this deployed filings to to two consumed is other and positive across transitioned that aggressively capital Genetics XXXX, $XX.X year-over-year solidify corporate is of our throughout candidates all happy initiatives. From our million Precigen Please Exemplar operations. throughout and divesting both our therapeutics company. recall Trans the corporate XX% operating XXXX our or adjusted Precigen reductions to our company of expenses Ova most to expenditures. segment million. which and to We objectives streamlining commercial cash reduced that capital net or As cost our suspending We're This report subsidiaries, of that operations ensure these capital balance and million our SEC a committed $XXX focused primary metric from and promising EBITDA sheet. operating metric, human our lead the our reflects requirement discontinued defined in by strong net as of generally and sum change performance expenditures primary in continued fully

of XX% away $XX.X improved discontinued subsidiaries our that corporate and our capital $XX revenue-generating operations Genetics were XX% that of main an assets by Specialty, Okinawan entity Exemplar platforms. our AEBITDA, in that we last $XX in without and that $XXX.X of Precigen achieved Ova we million XXXX such our early the will during requirements cash. sold $XX combined corresponding year's and Our contributors primary million. draw or candidates Segment to XXXX, or $XX need we than operations, or of million million neither January pleased year-over-year by MBP $XX.X by and assets no support. XXXX we required in XXXX, suspended impairing million capital We We from versus year-over-year. and and required any both operation Titan. include on Among committed a would XXXX more XX% two progress substantial XXXX respectively, These a that reduced are reduction clinical predominantly, more Oxitec longer than million in Precigen headcount Trans million as call continuing

pipeline continued that human electing organization. growing efficiency advance of maintain and anticipate our current our discipline strict capital remain entire in committed We're we requirements While therapeutic candidates the to sheet candidates to balance will our financial across strength. which with will increase the pleased support of

debt XXXX of we total completed began capital operating addition fast-paced anticipated we to candidate. our in In during in million turn to public equity and the $XX.X in of for support spend our will balance million XXXX, to underwritten continued I'd converting offering Helen. now $XXX.X for call focused with to approximately million. in resulting proceeds, Pro into this needs advancement that XXXX believe net common $XXX.X forma We recently cash. the like therapeutic to allowing increases required even catalyze back proceeds

Helen Sabzevari

Tom. our key another for year be you, to with for programs. initiations promises our many Thank anticipated readouts and data transformative XXXX company trial

We milestone into have these achieve this sufficient cash year on hand XXXX. to and

quickly We now remains to are therapeutics open committed on excited innovative Operator, entire our shareholders our patient, motivate as pipeline platform the and questions. goal day. forward line for as advance our of the team behalf may you to achieving us and of technology the possible every which

Operator

go from first We'll ahead. instructions] you. [Operator begin now Securities. the Please Butler question comes Our Thank JMP question-and-answer session. Jason with

Jason Butler

questions. taking for the thanks Hi,

in the patient dynamics inform trial? patient transplant the tumor development characteristics the First timeline or cytogenetics one any the more about about the response and there or patient subsequent you or anything or could color XXXX or on Helen, selection. us Anything that the with CRI give is future can

Helen Sabzevari

arm Thank exact, the actually you or the patient very have that dose. that million a the treated first considered dosed this it glad Definitely, patient was call. was be excited, this that lymphodepletion that PRGN-XXXX the October in the not in January, hematological MLS about of been in was the was received X.X put and believe was we close really evaluated completely patient this the with it had received. really in is a patient and you, Jason The overnight autologous when which cells it's To November we're on low to patient October of it patient was but to and followed fall let's in ACR Dr. and very I not yet way, correspondence -- patient R&D, gave so

the exciting marrow failed eligible bone patient this for count incomplete patient cells that the full could recovery would CRI, Solomon was receive the else patient, was because incomplete the that is hematological in cells this patient, had level without X%. that. the to these the referred patients blast for which not below to recovery. the hematological now the in no patient the back been recovery has mainly the AML the marrow been when complete which used well the the was actually X% and after very response basically receive blood the is no the blood consider the in be and the in platelet patient these considered as in to consequently bone they and has to this patient, follow-up. with it this basically It it's and and and there reevaluation very result complete There and this achieved marrow But and doing had everything went patient ultimate PR blast is the bone that below transplant marrow has patient received to the they had transplant now the immunological blast be bone the basically

in our lymphodepleted So with first treated excited especially a such of arm. dose we patient we're the in have UltraCAR-T that low a really

Jason Butler

And you're look for just to and more think or responses in cohorts the talk to then one profile, at doses? about context versus of seeing can how logos high may me, higher you already where you just continuing about you the expand want safety to how dose just the

Helen Sabzevari

a second have to and dose a finishing and we already depletion, kilogram we in and get we a the the which entered from depletion AML data what dose non-lympho X cohort. actually cohort decision Currently, to non-lympho million a third that and and patients treatment is and lymphoid will the per what both an in the communicated are depletion lympho at on for we we have expansion. evaluating we have those obviously we then as So cohort made that have up be depletion make we from follow following first then and we're going

Operator

comes question next Please with Stifel. go from ahead. Our Ben Burnett

Helen Sabzevari

you very Stifel analyst the group. and to you from the for welcome you. on to Group. our Thank being as want I Thank Ben, call much

Ben Burnett

for welcome and the appreciate you Thank I that.

patient in that actually maybe you clinical the just of these patient. mentioned previous I events with you some wanted on wondering if they did around of the I talk still cell discussion observed deemed some the CRI transplant, questions. being that transplant. to two CRI you in about like data the How correlate the and AML for Just wanted can at when CAR-T did follow-up have the expansion system? to their that was they

Helen Sabzevari

received period and patient a this So patient of the time we've this been second and was follow that point to there for cells in had able we a to good the their persistence up very of expansion cells.

unfortunately not this before transplant cells a have direct have from -- We this we patient. don't

also the patient a bone because I of the of is to criteria have I very well that we believe blast the expansion the but question, response cannot early received least exactly and has during two bone what and had time blast go the cells of persistence complete majority the months cells answer in bone good at through marrow months T and the So we to marrow a obviously below and the during and that's X% after expansion, actually and in expansion the marrow up that one that happened. the infusion saw for

Ben Burnett

you our a I I one guess and this primary it escalate you program, happening cell in guess sites. for to ovarian Maybe a what like one be expansion better to see do for terms tumor next metastatic so the one, this just or dose other as think what's the are caveat cancer readout this is may update data good proxy proxy of in expecting

Helen Sabzevari

when we're number IV of in we first IP are this in CAR-T reading, therefore, are blood. and the reading Excellent the question, the Ben. infusing Actually, we actually because not

the PRs and presented in the these the because well seen December XX% patients the bladder we failure was necessarily of and treatment reduction various XX on that did and it's patient, in we of the think to we patient, in in had definitely of we're burden expansion three distant seven the them infusing quite tumor prior more of like upwards of date show the being and kinetic sick of quite six, areas What for in some the XX% intraperitoneally. So we lesions impressive what I it is saw or they we have had number in as the upwards lesion. cells instance lesion blood of which some out of up tumor for effect direct CRs don't total of

that has and be the we and What in up now sought think but So on the we patients expansion we out. the could of blood allowed this persistence to I think readout, still been safety see I was just exciting will we call is months follow we that that major us to able three one started there and versus in is have to in FDA communicated show this could this the IV. concomitantly the based

and regionally to before permission well. we recall, you more to the that and the persistence sought we start have FDA following as the received finish in we think and to will completely be we color get now had have the IVR access kinetics dosed patient we excited our way the of will were first we really If IV IPR IV and I expansion

Operator

Abbott ahead. from Please Wells go Fargo comes Nick Securities. Our question next with

Chuck Whitesell

I those counter Abbott. for other Chuck AdenoVerse well. Nick as one specifically how elaborate two for HPV is Nick and PRGN-XXXX you're actually vaccines? had questions, you on on It's for welcome Thank your appreciates you from platform, differentiating could Whitesell the

Helen Sabzevari

or in it's because or So our sense them times vectors five give or positivity zero general. very can at gorilla AdenoVerse other in no platform you that first there the human, is little number in zero platform, this of all, of differentiated positivity retroviruses unlike a

we model. Here that before you expend you can keep interjecting had can T-cell and in preclinical pre-clinically shown the

than there. the that differentiation So using of is anything out that gorilla, our that the platform for PRGN-XXXX factor is first

different the Generally else we epitope expend is JPMorgan NCR, profile we breadth years have incorporated the and through PRGN-XXXX the you of they exactly the what the companies in we have virus in majority differentiation that from and a can part all we this preliminary shown is in use in monotherapy, last we really made first and HPV. same. that think new basically number a you are and of safety fact and the now have targeted done with safety over of have predicted, repeat with -- competitors. part a the PRGN-XXXX our second no that we are that keep that is before year also there have showed in that were PRGN-XXXX of of excited that the but is only that really really antigen the for has the that factor and the incorporated one T-cell what not time of we for data excellent basically the our we that I The identified other shown the the we really What lot bioinformatics dose antigen second targeted increasing was versusall as that the and to is what of when

Chuck Whitesell

certain my second your you is general And strategy partnering elaborate assets? for could on question

Helen Sabzevari

when to assets to from so data have get be of level. what to the a philosophy certain Absolutely you able actually partnering pharma, is the especially, we be aware the have come in level maturity always the to also may in speaks you asset clinical general and be in that to is for presented big be especially on regard to at it

and for we In in focus some regard eventually we time. of to have that the targets patient have the So period built know very all for what done the of maximize years, launches ability the have a we already. and diverse for data platform we bringing in preclinical built have what done and for a the we two assets, the success past portfolio high certain that these then clinical to that over on our believed and was it we has that's instance with solid assets first clinic of

we in we on is Phase XXXX, we stage, oncology other been have, cardiac of the a after partner These focus X has our like in perhaps targets look in that targets preclinical focused currently diseases. to finishing and Some all and some infectious for which for ultra-immunity the the our safety XXXX be and and asset. very encouraging a saw in data for with we I that reporting the that's we for will fit have which it's year, very mentioned, a this discussion are for for as that instance from partnership good X partnership Phase what inter and we assets best field

think and value So mind, we're a that our dataset decision the and would we portfolio move. I evaluating and opportunity of continuously at come as that look of and partnerships and maturity evaluate in the strategically the make we with they the up, also

Operator

next question Joseph Please Eric JPMorgan. comes ahead. Our with from go

Hannah Adeoye

Hannah Thanks taking our for question. for This Eric. on is

given regimen? date, pursuing more just First interest and consider have lymphodepletion used any safety to if with regimen seeing in you the any wondering changes a you XXXX would rigorous your data do being that's the to

Helen Sabzevari

ultracard hospital not lymphodepletion data, only basically Well biomarker with decrease actually bone somewhere expand with and to went XX of expansion on ultracard cells cells non-lymphodepletion was conjunction which the the million seven preliminary black came and samples patient need vote that increase also in cells that rigorous we've a directly exciting to blood marrow honest arm, peripheral seen on the a persistence be we that don’t of have, you but attached the basic for is and the we patient mine our in of very in we reported receive with over pursue patient more patient, last regiment in even conjunction because and in or that the T-Cell directly cytotoxicity of out the persist the this and cells also against these around to the peripheral showed to tumors. to in the

we that based regular Do regimen, we and and expansion dose right think do we without arm without this the that. think we not an finish go to we evaluate depletion lymphodepletion then the we lymphodepletion I is have expansion. I we will need aggressive one and I lymphodepletion? So now which an think lymphoid will would have Can on and

lymphodepletion. So for a I don't more reason see aggressive any

Operator

Please [Operator instructions] with ahead. Our Wainwright. next question HC Arthur go He comes from

Arthur He

had on Ash the for business XXX the I update Thank us way, two first and data the study follow-up you patients give already just last your question could in the year second questions, decent strategies give an a case along presented could regarding secured you Ova the you update you. us regarding Exemplar? on Trans guys cash is an and considering the at

Helen Sabzevari

I in believe have the to patients refer I think on this Dr. to I the back Ash

Solomon as a follow-up.

I any give that wrong. to I don't kind make information that just So is sure want of

So the update you patient, we and as that followed at we which can in on that reports the I patient gotten just have time. report tell R&D

that into definitely to look get regard I'll So and in back update. you to that

can speak for As as have to our financial strategy, we Tom that. think I

to mentioned to XXXX want a runway you add? and have Tom good now if have we we As

Tom Samuelson

of the also have where the really flourishing talked I the subsidiaries so. position we of a Both the all of Yeah year well mind the excited the beginning our been are our that at and think in one revenue operating of to putting with generating about businesses in was and will made of contributing both businesses them. we've progress very on continue cash have do performing and we're things

So I what strategic we both particular shared. any side beyond updates I've on the businesses have for wouldn’t say

Operator

Justin Walsh Securities. comes B. Please question ahead. from with Our Riley next go

Justin Walsh

and the trial for cell but is the So cancers moving need that indications know obviously various with have I sinonasal PRGN-XXXX, asset? about cancer, II and my what NCI to see question driven what into is the Phase signals you you the to the there? oropharyngeal HPV squamous put first a thought the portion were cancers other any cervical really positive HPV

Helen Sabzevari

really six trial our positive. all about excited we're the you first know because HPV patients this Actually question. AdenoVerse in as PRGN-XXXX with commerce were Excellent

that's the cervical we had and and the we epitopes actually this but currently of the them cancers would design because And not neck, head only this T-cells ability The are like this and area again this not really and that the and capability these and again expansion the and regard the I were also was of giving your before to looking with among AdenoVerse just I cancer coverage by to very also had to the platform patients and over number repeated T-cells it things platforms So with expanding the patient at coverage this sort to that advanced over that over for cervical generated. specific heading PRGN-XXXX payload covers when directly have and in and is of to one of entering is all the it that in one to vaccines have very, this the like allows itself epitopes. way, that vaccines very the generate mention over has being exciting. and the us PCRs I PRGN-XXXX, unique that vaccine the also expanded for allows platform keep in mentioned but of of dosing as its especially that keep lends very, is

will very Phase only I would the cervical be be stay upcoming half reporting but also and in moving this are definitely cancers of to tuned. as year will in II towards year be NCI we going Phase and addressing It's not the X the second and result of head say in So neck on we exciting. in

Justin Walsh

you. very question helpful That's me. for Thank and last

provide a go on reality combination potential your like Can regulatory it might is compelling. expression So with antigen having selected that? regulators of Would color antigens we multiple each of the used something review for CAR treatment from for immediately might some UltraCAR-T to neoantigen think get or need approach? like more through vision patient concept of to tumor-associated having you on of rounds how really and a

Helen Sabzevari

what you exactly mentioned is is this think I correct.

are way trial Identify will it with right? that you point, antigen be further discussions that we setup weeks for antigens the don't having more to and FDA neoantigen you and among built to in the indications multiple different a but UltraVectors By weeks instance. your and for to new discussing might need. neoantigen, with here will We the the need be that TCR like produce are that difference TCRs various shared then upon by

be see that we have the of any part the have and pancreatic, you to bladder you have and of that overnight MUCXX, you have, library and gone produce infuse of can the and is that day across patient. shared shown overnight we at you MUCX, you can the look you already combinations have for with have cancer you basically these lung, can we can this these through antigens or the next the can QC can If in indications mesothelioma these ovarian, manufacturing important of and do number and of any can

as we We finishing are, dosing. our speak,

the the cells establishing as patient and for one as having we basically being generated infused safety and then molecular coming profile I the having the that FDA indications think to side with on they clinic are the ovarian can hematological solid and tested our redosed AML, tumors in the the So mixture in an the are using of and what doses umbrella have we well from different then cancer in indication that a have. this on of depending what these the discussions we consider that tumor trial or data the of is or the both I have you

about antigens our don't accessible point of that your correct, but using TCR have UltraVector. to are with obstacles the we any So neoantigens have that because the are library the we that the difference neoantigens are easily of

dose. overnight many at it's as manufacture doses we can is manufacturing and and needed as Our needed are we can that the repeat

Operator

to for Sabzevari remarks. like closing This conference session. I concludes turn Helen our question-and-answer to over any the would back

Helen Sabzevari

very much. you Thank

of to and you months. with look to to the meet First time the providing conferences scientific call questions. thank our thoughtful for listen We the in taking and everyone updates and coming at for forward all, upcoming investor want I to the to

very look about are our We we programs to and Thank investors. our interactions basically and our forward excited our you. next analysts with

Operator

Thank today's has The concluded. attending now conference presentation. for you

You now disconnect. may

Precigen (PGEN) 2 Mar 212020 Q4 Earnings call transcript